GSK
846 hedge funds and large institutions have $11.7B invested in GSK in 2019 Q1 according to their latest regulatory filings, with 112 funds opening new positions, 313 increasing their positions, 263 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
846
Holders Change
+48
Holders Change %
+6.02%
% of All Funds
18.34%
Holding in Top 10
14
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-17.65%
% of All Funds
0.3%
New
112
Increased
313
Reduced
263
Closed
56
Calls
$178M
Puts
$67.7M
Net Calls
+$111M
Net Calls Change
+$77.1M
Top Buyers
| 1 |
Capital International Investors
Los Angeles,
California
|
+$133M |
| 2 |
Renaissance Technologies
New York
|
+$110M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$71.7M |
| 4 |
Two Sigma Investments
New York
|
+$39.8M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$34.3M |
Top Sellers
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$236M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$76.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$51.5M |
| 4 |
Jane Street
New York
|
-$47.1M |
| 5 |
WIC
Willis Investment Counsel
Gainesville,
Georgia
|
-$38.4M |
